This analysis used propensity score matching of subjects from randomized placebo-controlled schizophrenia studies to compare paliperidone ER 6–12 mg/day with risperidone 2–4 mg/day and risperidone 4–6 ...

Switching to UZEDY at four weeks after the last dose of once-monthly paliperidone palmitate provided the most comparable pharmacokinetic (PK) profile based on the relevant PK modeling data Additional ...

TITUSVILLE, N.J., May 24 /PRNewswire/ --New data on INVEGA® SUSTENNA® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on RISPERDAL® CONSTA® (risperidone ...

Paliperidone 3 mg, 6 mg, 9 mg; extended-release tabs. Paliperidone is the major active metabolite of risperidone. Although the mechanism of action of this atypical antipsychotic is unknown, the ...

Janssen, L.P.'s INVEGA Approved By FDA As New Treatment For Schizophrenia TITUSVILLE, N.J., Dec. 20 /PRNewswire/ -- First Oral Extended Release Medication to Treat Schizophrenia. The U.S. Food and ...

Trial is the first to study schizophrenia treatment within the context of many real-world issues faced by patients with schizophrenia TITUSVILLE, N.J., April 15, 2015 /PRNewswire/ -- A study published ...

Drug cleared for maintenance therapy in adult patients responding or stabilized with oral paliperidone or risperidone. The EC has approved Janssen-Cilag’s Xeplion® (paliperidone palmitate) ...

The current study provides a novel in-depth assessment of the extent of antipsychotic drugs transport across the blood–brain barrier (BBB) into various brain regions, as well as across the ...

Background: To compare the efficacy and tolerability of paliperidone extended-release (ER) with risperidone immediate-release using propensity score methodology. Methods: Six double-blind, randomized, ...

Presentations include data informing clinical strategies for switching patients to UZEDY, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the ...